Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | P2RY1 | P47900 | 14/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diflufenican SCHEMBL22023 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| Diflufenican SCHEMBL29549369 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| Diflufenican SCHEMBL29373740 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| Diflufenican SCHEMBL28864547 | 0.96 | KMT2A (0.93) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| Diflufenican SCHEMBL21295280 | 0.94 | KMT2A (0.88) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| Diflufenican SCHEMBL7534513 | 0.91 | KMT2A (0.83) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| SCHEMBL10968288 | 0.90 | KDM4E (0.81) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| SCHEMBL10970533 | 0.90 | KMT2A (0.81) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| SCHEMBL9616229 | 0.88 | KMT2A (0.79) | KMT2AKDM4EMEN1CYP1A2CYP2C19 | |
| SCHEMBL10968980 | 0.88 | KDM4E (0.79) | KMT2AKDM4EMEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197477-B2 | Aqueous capsule suspension concentrates based on 2-[(2,4-dichlorophenyl)methyl]-4,4′-dimethyl-3-isoxazolidinone | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-12-14 | — | — | US | disclosed |
| EP-3787407-A1 | AQUEOUS CAPSULE SUSPENSION CONCENTRATES CONTAINING A HERBICIDAL SAFENER AND A PESTICIDAL ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2021-03-10 | — | — | EP | disclosed |
| EP-3697221-A1 | AQUEOUS [2-(2,4-DICHLOROPHENYL)METHYL]-4,4-DIMETHYL-3-ISOXAZOLIDINONE-BASED SUSPENSION CONCENTRATES | Bayer Aktiengesellschaft (DE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3402332-B1 | AQUEOUS DISPERSIONS COMPRISING ACLONIFEN AND FLUFENACET | BAYER CROPSCIENCE AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-20190200614-A1 | AQUEOUS CAPSULE SUSPENSION CONCENTRATES BASED ON 2-[(2,4-DICHLOROPHENYL)METHYL]-4,4'-DIMETHYL-3-ISOXAZOLIDINONE | FMC CORPORATION | 2019-07-04 | — | — | US | disclosed |
| EP-3493677-A1 | AQUEOUS 2-(2,4-DICHLOROPHENYL)METHYL -4,4-DIMETHYL-3-ISOXAZOLIDINONE-BASED CAPSULE SUSPENSION CONCENTRATES | Bayer CropScience Aktiengesellschaft (DE) | 2019-06-12 | — | — | EP | disclosed |
| WO-2019076744-A1 | AQUEOUS [2-(2,4-DICHLOROPHENYL)METHYL]-4,4-DIMETHYL-3-ISOXAZOLIDINONE-BASED SUSPENSION CONCENTRATES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-04-25 | — | — | WO | disclosed |
| US-20190053484-A1 | SOLVENT-FREE FORMULATIONS OF LOW-MELTING ACTIVE INGREDIENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-21 | — | — | US | disclosed |
| US-20190021311-A1 | AQUEOUS DISPERSIONS COMPRISING ACLONIFEN AND FLUFENACET | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-01-24 | — | — | US | disclosed |
| EP-3419418-A1 | SOLVENT-FREE FORMULATIONS OF LOW-MELTING ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-01-02 | — | — | EP | disclosed |
| EP-0575503-A1 | HERBICIDAL PYRIDINE SULFONAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| EP-0574418-A1 | ARYL SULPHONYL UREA COMPOUNDS, A METHOD OF PREPARING THEM, AND THEIR USE AS HERBICIDES AND GROWTH REGULATORS | Hoechst Schering AgrEvo GmbH (DE) | 1993-12-22 | — | — | EP | disclosed |
| WO-1992020684-A1 | HERBICIDAL OXATRICYCLIC ETHERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992015576-A1 | HERBICIDAL PYRIDINE SULFONAMIDE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
| WO-1992013845-A1 | ARYL SULPHONYL UREA COMPOUNDS, A METHOD OF PREPARING THEM, AND THEIR USE AS HERBICIDES AND GROWTH REGULATORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992013861-A1 | HERBICIDAL BICYCLIC ETHERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992010501-A1 | HERBICIDAL ETHERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992009587-A1 | HERBICIDAL OXAZINE ETHERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009578-A1 | SUBSTITUTED FUSED HETEROCYCLIC HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5041681-A | Preparation of Substituted Cyclohexanetrione Herbicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190200614-A1 | AQUEOUS CAPSULE SUSPENSION CONCENTRATES BASED ON 2-[(2,4-DICHLOROPHENYL)METHYL]-4,4'-DIMETHYL-3-ISOXAZOLIDINONE | ACMSD, DDT, CCND2 | KMT2A 537/4885KDM4E 320/4885MEN1 3046/4885 |
| US-20190053484-A1 | SOLVENT-FREE FORMULATIONS OF LOW-MELTING ACTIVE INGREDIENTS | CYP51A1, ABCG2, FASTKD5 | KMT2A 3788/4885KDM4E 3939/4885MEN1 3605/4885 |
| US-11197477-B2 | Aqueous capsule suspension concentrates based on 2-[(2,4-dichlorophenyl)methyl]-4,4′-dimethyl-3-isoxazolidinone | ACMSD, DDT, CCND2 | KMT2A 541/4885KDM4E 320/4885MEN1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.